Edition:
United Kingdom

Corbus Pharmaceuticals Holdings Inc (CRBP.OQ)

CRBP.OQ on NASDAQ Stock Exchange Global Market

5.95USD
21 May 2018
Change (% chg)

$-0.22 (-3.64%)
Prev Close
$6.18
Open
$6.15
Day's High
$6.20
Day's Low
$5.95
Volume
45,804
Avg. Vol
140,360
52-wk High
$9.85
52-wk Low
$5.05

Select another date:

Thu, May 10 2018

BRIEF-Corbus Pharmaceuticals Reports Q1 Loss Per Share $0.21

* CORBUS PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Corbus Pharmaceuticals Reports 2017 Financial Results And Provides Clinical Update

* CORBUS PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE

BRIEF-Corbus Pharmaceuticals Receives $25 Mln Development Award From The Cystic Fibrosis Foundation

* CORBUS PHARMACEUTICALS RECEIVES $25 MILLION DEVELOPMENT AWARD FROM THE CYSTIC FIBROSIS FOUNDATION TO SUPPORT PHASE 2B CLINICAL STUDY OF LENABASUM Source text for Eikon: Further company coverage:

BRIEF-Corbus Agrees With FDA On Phase 2B Cystic Fibrosis Study Design With Pulmonary Exacerbations As Sole Primary Endpoint

* CORBUS PHARMACEUTICALS ANNOUNCES AGREEMENT WITH FDA ON PHASE 2B CYSTIC FIBROSIS STUDY DESIGN WITH PULMONARY EXACERBATIONS AS SOLE PRIMARY ENDPOINT

Corbus cystic fibrosis drug to get FDA review on flare-up data

Corbus Pharmaceuticals Holdings Inc said on Monday the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function, dramatically cutting the time and cost it will take Corbus to develop the drug.

Corbus cystic fibrosis drug to get U.S. FDA review on flare-up data

Jan 29 Corbus Pharmaceuticals Holdings Inc said on Monday the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function, dramatically cutting the time and cost it will take Corbus to develop the drug.

BRIEF-Corbus Pharmaceuticals Files For Mixed Shelf Of Up To $200 Mln ‍​

* CORBUS PHARMACEUTICALS HOLDINGS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING ‍​ Source text: (http://bit.ly/2EciBBu) Further company coverage:

BRIEF-Corbus Pharma Initiates Phase 2 Study Of Anabasum For Treatment Of Systemic Lupus Erythematosus

* CORBUS PHARMACEUTICALS ANNOUNCES INITIATION OF PHASE 2 STUDY OF ANABASUM FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS Source text for Eikon: Further company coverage:

Select another date: